Four EIA-kits for the detection of SARS-CoV-2 antibodies, manufactured by RPC “Diagnostic Systems”, have obtained CE-mark
In this challenging time of the coronavirus pandemic, RPC “Diagnostic Systems”, Ltd in no time developed four enzyme immunoassay kits aimed at the detection of SARS-CoV-2-specific antibodies causing novel COVID-19 and started placing their products on the international market:
- reagent kit cat# S-2372/1.1 “DS-ÅIA-ANTI-SARS-CoV-2” for the detection of antibodies to SARS-CoV-2 in human serum or plasma;
- reagent kit cat# S-2382/1.1 “DS-ÅIA-ANTI-SARS-CoV-2-G” for the detection of IgG antibodies to SARS-CoV-2 in human serum or plasma;
- reagent kit cat# S-2442/1.1 “DS-ÅIA-ANTI-SARS-CoV-2-G (S)” for the detection of IgG antibodies to the SARS-CoV-2 spike protein in human serum or plasma.
- reagent kit cat# S-2431/1.1 “DS-ÅIA-ANTI-SARS-CoV-2-SPECTRUM” for the detection of IgM, IgA, IgG antibodies to SARS-CoV-2 in human serum or plasma.
For the mentioned RPC “Diagnostic Systems” medical devices, the Declaration of Conformity has been signed to declare compliance of the products with the EU law - Directive 98/79/EC on in vitro diagnostic medical devices. The four kits are CE-marked that indicates the product conformity for sales in Europe and that it is available for order.
The application of the kits in the EU healthcare practices can enable the diagnosis of the current infection in combination with other tests, the assessment of immune response to the past COVID-19 and differential assessment of the humoral immune response before and after vaccination.
For further information about the kits, contact the Customer Service at the 8-800-555-03-00 (7626, 7655) toll-free hotline or write an e-mail: firstname.lastname@example.org; email@example.com (Head of Promotion Department – Irina Golubeva).